A
A
    Global websites
    Local websites
    language header world map

    Case Studies

    Efgartigimod

    Target:
    FcRn

    Efgartigimod (ARGX-113) was designed as a human IgG1 antibody Fc-fragment, a natural ligand of the neonatal Fc receptor (FcRn). FcRn is known to extend half-life and availability of pathogenic IgG antibodies.

    Efgartigimod has been engineered for increased affinity to FcRn and was built in collaboration with Prof. E. Sally Ward, Ph.D. who is a pioneer of FcRn biology.

    Read more
    ARGX-118

    Target:
    Galectin-10

    ARGX-118 was designed as a highly differentiated antibody against Galectin-10, the protein of Charcot-Leyden crystals, which are implicated as a major contributor to severe asthma and to the persistence of mucus plugs.

    ARGX-118 was built in collaboration with Prof. Bart Lambrecht, M.D., Ph.D. who identified the first novel airway inflammation target in decades.

    Read more
    ARGX-115

    Target:
    GARP

    ARGX-115 (now ABBV-151) was designed as a humanized monoclonal antibody inhibitor of GARP- TGF-β1 and is in development by AbbVie for the treatment of cancer.

    ARGX-115 was built in collaboration with Prof. Sophie Lucas, M.D., Ph.D. who has been a leader in checkpoint biology research since 1985.

    Read more